
Gesynta Pharma Hits Halfway Mark in Phase 2 Endometriosis Study
Swedish pharmaceutical firm Gesynta Pharma has reached a critical recruitment milestone, enrolling 50% of the 190 patients required for its Phase 2 trial of vipoglanstat. The study, known as NOVA, evaluates a non-hormonal, non-opioid candidate designed to address the chronic pain and inflammation associated with endometriosis.






















